Impact of preoperative leukocyte alteration in surgically-treatedearly-stage cervical cancer patients with low-risk, intermediate-risk or high-risk factors

Purpose: The aim of this study was to investigate the prognostic impact of a preoperative leukocyte alteration in patients with surgically- treated early-stage cervical cancer. Materials and Methods: The baseline characteristics and outcome data of early-stage cervical cancer patients who were treated with radical hysterectomy between 1996 and 2011 were collected and retrospectively reviewed. The patients were separated into three risk groups (low-risk, intermediate-risk, and high-risk) according to the pathological risk factors exhibited by their tumors. A Cox proportional hazards regression model was used to investigate the prognostic significance of a preoperative leukocytosis (≥ 10,000 μ/l). Results: A preoperative leukocytosis was observed in 0.9%, 6.6%, and 8.6% of the patients in the low-risk, intermediate-risk, and high-risk groups, respectively. In multivariate analysis, a preoperative leukocytosis was found to be an independent prognostic factor in intermediate-risk or high-risk groups. Conclusion: The preoperative leukocytosis is an independent predicator of shorter progression-free survival (PFS) in surgically-treated early-stage cervical cancer patients, especially those with intermediate-risk or high-risk factors.

eukocytosis; Cervical cancer; Radical surgery; Survival.

[1] Landoni F., Maneo A., Colombo A., Placa F., Milani R., Perego P., et al.: “Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer”. Lancet, 1997, 350, 535.

[2] Morley G.W., Seski J.C.: “Radical pelvic surgery versus radiation therapy for stage I carcinoma of the cervix (exclusive of microinvasion)”. Am. J. Obstet. Gynecol., 1976, 126, 785.

[3] Perez C.A., Camel H.M., Kao M.S., Hederman M.A.: “Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report”. Gynecol. Oncol., 1987, 27, 129.

[4] Benedet J.L., Odicino F., Maisonneuve P., Beller U., Creasman W.T., Heintz A.P., et al.: “Carcinoma of the cervix uteri”. Int. J. Gynaecol. Obstet., 2003, 83, 41.

[5] Kasamatsu T., Onda T., Sawada M., Kato T., Ikeda S.: “Radical hysterectomy for FIGO stage IIB cervical cancer: clinicopathological characteristics and prognostic evaluation”. Gynecol. Oncol., 2009, 114, 69.

[6] Delgado G., Bundy B., Zaino R., Sevin B.U., Creasman W.T., Major F.: “Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study”. Gynecol. Oncol., 1990, 38, 352.

[7] Fuller A.F., Jr., Elliott N., Kosloff C., Hoskins W.J., Lewis J.L. Jr.: “Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix”. Gynecol. Oncol., 1989, 33, 34.

[8] Samlal R.A., van der Velden J., Schilthuis M.S., González D., Ten Kate F.J., Hart A.A., et al.: “Identification of high-risk groups among node-positive patients with stage IB and IIA cervical carcinoma”. Gynecol. Oncol., 1997, 64, 463.

[9] Peters W.A. 3rd, Liu P.Y., Barrett R.J. 2nd, Stock R.J., Monk B.J., Berek J.S., et al.: “Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix”. J Clin Oncol., 2000, 18, 1606.

[10] Rotman M., Sedlis A., Piedmonte M.R., Bundy B., Lentz S.S., Muderspach L.I., et al.: “A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study”. Int. J. Radiat. Oncol. Biol. Phys., 2006, 65, 169.

[11] Sedlis A., Bundy B.N., Rotman M.Z., Lentz S.S., Muderspach L.I., Zaino R.J.: “A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study”. Gynecol. Oncol., 1999, 73, 177.

[12] Kim K., Kang S.B., Chung H.H., Kim J.W., Park N.H., Song Y.S.: “Comparison of chemoradiation with radiation as postoperative adjuvant therapy in cervical cancer patients with intermediate-risk factors”. Eur. J. Surg. Oncol., 2009, 35, 192.

[13] Ryu S.Y., Park S.I., Nam B.H., Cho C.K., Kim K., Kim B.J., et al.: “Is adjuvant chemoradiotherapy overtreatment in cervical cancer patients with intermediate risk factors?” Int. J. Radiat. Oncol. Biol. Phys., 2011, 79, 794.

[14] Song S., Song C., Kim H.J., Wu H.G., Kim J.H., Park N.H., et al.: “20 year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: impact of treatment period and concurrent chemotherapy”. Gynecol. Oncol. 2012, 124, 63.

[15] National Cancer Institute: “NCT01101451 - Clinical Trial”. Available at: www.cancer.gov/clinicaltrials/search/view?cdrid=670125&version=HealthProfessional&protocolsearchid=10780359

[16] Granger J.M., Kontoyiannis D.P.: “Etiology and Outcome of Extreme Leukocytosis in 758 Nonhematologic Cancer Patients; A Retrospective, Single-Institution Study”. Cancer, 2009, 115, 3919.

[17] Mabuchi S., Matsumoto Y., Isohashi S., Yoshioka Y., Ohashi H., Morii E., et al.: “Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer”. Gynecol. Oncol., 2011, 122, 25.

[18] Mabuchi S., Matsumoto Y., Hamasaki T., Kawano M., Hisamatsu T., Mutch D.G., et al.: “Elevated white blood cell count at the time of recurrence diagnosis is an indicator of short survival in patients with recurrent cervical cancer”. Int J Gynecol Cancer, 2012, 22, 1545.

[19] Mabuchi S., Matsumoto Y., Kawano M., Minami K., Seo Y., Sasano T., et al.: “Uterine cervical cancer displaying tumor-related leukocytosis: a distinct clinical entity with radioresistant feature”. J. Natl. Cancer Inst., 2014, 106. pii: dju147. doi: 10.1093/jnci/dju147. Print 2014 Jul.

[20] Kawano M., Mabuchi S., Matsumoto Y., Sasano T., Takahashi R., Kuroda H., et al.: “The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer”. Sci. Rep., 2015, 15, 18217.

[21] Mabuchi S., Okazawa M., Isohashi F., Matsuo K., Ohta Y., Suzuki O., et al.: “Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage IIB cervical cancer”. Gynecol. Oncol., 2011, 123, 241.

[22] Okazawa M., Mabuchi S., Isohashi F., Suzuki O., Yoshioka Y., Sasano T., et al.: “Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience”. Int. J. Gynecol. Cancer, 2013, 23, 567.

[23] Mabuchi S., Okazawa M., Matsuo K., Kawano M., Suzuki O., Miyatake T., et al.: “Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: Adenocarcinoma versus squamous cell carcinoma”. Gynecol. Oncol., 2012, 127, 114.

[24] Isohashi F., Yoshioka Y., Mabuchi S., Konishi K., Koizumi M., Takahashi Y., et al.: “Dose-volume histogram predictors of chronic gastrointestinal complications after radical hysterectomy and postoperative concurrent nedaplatin-based chemoradiation therapy for early-stage cervical cancer”. Int. J. Radiat. Oncol. Biol. Phys., 2013, 85, 728.

[25] Isohashi F., Mabuchi S., Yoshioka Y., Seo Y., Suzuki O., Tamari K., et al.: “Intensity-modulated radiation therapy versus three-dimensional conformal radiation therapy with concurrent nedaplatin-based chemotherapy after radical hysterectomy for uterine cervical cancer: comparison of outcomes, complications, and dose-volume histogram parameters”. Radiat. Oncol., 2015, 10, 180.

[26] Mabuchi S., Morishige K., Isohashi F., Yoshioka Y., Takeda T., Yamamoto T., et al.: “Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors”. Gynecol. Oncol., 2009, 115, 482.

[27] Mabuchi S., Okazawa M., Isohashi F., Ohta Y., Maruoka S., Yoshioka Y., et al.: “Postoperative whole pelvic radiotherapy plus concurrent chemotherapy versus extended-field irradiation for early-stage cervical cancer patients with multiple pelvic lymph node metastases”. Gynecol. Oncol., 2011, 120, 94.

[28] Okazawa M., Mabuchi S., Isohashi F., Suzuki O., Ohta Y., Fujita M., et al.: “The prognostic significance of multiple pelvic node metastases in cervical cancer patients treated with radical hysterectomy plus adjuvant chemoradiotherapy”. Int. J. Gynecol. Cancer, 2012, 22, 490.

[29] Mabuchi S., Kimura T.: “Nedaplatin: a radiosensitizing agent for patients with cervical cancer”. Chemother. Res. Pract., 2011, 2011, 963159.

[30] Mabuchi S., Isohashi F., Yoshioka Y., Temma K., Takeda T., Yamamoto T., et al.: “Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy”. Int. J. Gynecol. Cancer, 2010, 20, 834.

[31] Lee Y.Y., Choi C.H., Sung C.O., Do I.G., Hub S.J., Kim H.J., et al.: “Clinical significance of changes in peripheral lymphocyte count after surgery in early cervical cancer”. Gynecol. Oncol., 2012, 127, 107.

[32] Zhang Y., Wang L., Liu Y., Wang S., Shang P., Gao Y., et al.: “Preoperative neutrophil-lymphocyte ratio before platelet-lymphocyte ratio predicts clinical outcome in patients with cervical cancer treated with initial radical surgery”. Int. J. Gynecol. Cancer, 2014, 24, 1319.

[33] Wang D., Wu M., Feng F.Z., Huang H.F., Yang J.X., Shen K., et al.: “Pretreatment neutrophil-to-lymphocyte and platelet-tolymphocyte ratios do not predict survival in patients with cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy”. Chin. Med. J. (Engl.), 2013, 126, 1464.

[34] Wilcox R.A.: “Cancer-associated myeloproliferation: old associa tion, new therapeutic target”. Mayo Clin. Proc., 2010, 85, 656.

[35] Stone S.C., Rossetti R.A., Lima A.M., Lepique A.P.: “HPV associated tumor cell control tumor microenvironment and leukocytosis in experimental models”. Immun. Inflamm. Dis., 2014, 2, 63.

[36] Moses K., Brandau S.: “Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells”. Semin. Immunol., 2016, 28, 187.

[37] Qing L., Xiang T., Guofu Z., Weiwei F.: “Leukemoid reaction in cervical cancer: a case report and review of the literature”. BMC Cancer, 2014, 14, 670.